Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Related Disorders

  • Chapter
  • First Online:
Neuromuscular Disorders in Clinical Practice

Abstract

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy with several variants. Most are responsive to immunosuppressive or immunomodulating agents. This chapter discusses CIDP and its variants with emphasis on definition, etiology, pathogenesis, and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hoestermann E. On recurring polyneuritis. Dtsche Z Nervenheikd. 1914;51:116–23.

    Google Scholar 

  2. Roussy G, Cornil L. Progressive hypertrophic non-familial neuritis in adults. Ann Med. 1919;6:206–305.

    Google Scholar 

  3. Austin JH. Recurrent polyneuropathies and their corticosteroid treatment. Brain. 1958;81:157–92.

    PubMed  CAS  Google Scholar 

  4. Thomas PK, Lascelles RG, Hallpike JF, Hewer RL. Recurrent and chronic relapsing Guillain-Barré polyneuritis. Brain. 1969;92:589–606.

    PubMed  CAS  Google Scholar 

  5. DeVivo DC, Engel WK. Remarkable recovery of a steroid-responsive recurrent polyneuropathy. J Neurol Neurosurg Psychiatry. 1970;33:62–9.

    PubMed  CAS  Google Scholar 

  6. Matthews WB, Howell DA, Hughes RC. Relapsing corticosteroid-dependent polyneuritis. J Neurol Neurosurg Psychiatry. 1970;33:330–7.

    PubMed  CAS  Google Scholar 

  7. Mehndiratta MM, Hughes RAC. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2002;(1):CD002062.

    Google Scholar 

  8. Mehndiratta MM, Hughes RAC, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2004;(3):CD003906.

    Google Scholar 

  9. Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2009;(1):CD001797.

    Google Scholar 

  10. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975;50:621–37.

    PubMed  CAS  Google Scholar 

  11. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci. 1976;27:427–58.

    PubMed  CAS  Google Scholar 

  12. Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol. 1981;9(Suppl):134–45.

    PubMed  Google Scholar 

  13. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and electrophysiological study of 92 cases. Brain. 1987;110:1617–30.

    PubMed  Google Scholar 

  14. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46:878–84.

    PubMed  CAS  Google Scholar 

  15. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology. 1993;43:2202–9.

    PubMed  CAS  Google Scholar 

  16. Hahn AF, Hartung H-P, Dyck PJ. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy. 4th ed. Philadelphia: Elsevier/Saunders; 2005. p. 2221–53.

    Google Scholar 

  17. Köller H, Kieseier BC, Jander S, Hartung H-P. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352:1343–56.

    PubMed  Google Scholar 

  18. Said G. Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord. 2006;16:293–303.

    PubMed  Google Scholar 

  19. Vallat J-M, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010;9:402–12.

    PubMed  Google Scholar 

  20. Rotta FT, Sussman AT, Bradley WG, Ayyar DR, Sharma KR, Shebert RT. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2000;173:129–39.

    PubMed  CAS  Google Scholar 

  21. Bushby M, Donaghy M. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J Neurol. 2003;250:714–24.

    Google Scholar 

  22. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve. 2001;24:311–24.

    PubMed  CAS  Google Scholar 

  23. Kusumi M, Nakashima K, Nakayama H, Takahashi K. Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tottori Prefecture, Japan. Psychiatry Clin Neurosci. 1995;49:169–74.

    PubMed  CAS  Google Scholar 

  24. Lunn MPT, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry. 1999;66:677–80.

    PubMed  CAS  Google Scholar 

  25. Chiò A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007;78(12):1349–53.

    PubMed  Google Scholar 

  26. Laughlin RS, Dyck PJ, Melton 3rd LJ, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the associations with diabetes mellitus. Neurology. 2009;73:39–45.

    PubMed  CAS  Google Scholar 

  27. Rajabally YA, Simpson BJ, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of UK population. Muscle Nerve. 2009;39:432–8.

    PubMed  Google Scholar 

  28. Hughes RAC, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2006;11:30–46.

    PubMed  Google Scholar 

  29. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997;48:321–8.

    PubMed  CAS  Google Scholar 

  30. Pollard JD, Selby G. Relapsing neuropathy due to tetanus toxoid: report of a case. J Neurol Sci. 1978;37:113–25.

    PubMed  CAS  Google Scholar 

  31. Hughes RA, Choudhary PP, Osborne M, Rees JH, Sanders EA. Immunization and risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1996;19:1230–1.

    PubMed  CAS  Google Scholar 

  32. Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst. 2009;14:310–5.

    PubMed  Google Scholar 

  33. Andersonn T, Siden A. A clinical study of the Guillain-Barré syndrome. Acta Neurol Scand. 1982;66:316–7.

    Google Scholar 

  34. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré syndrome. Philadelphia: FA Davis; 1991. p. 57.

    Google Scholar 

  35. Schneider-Hohendorf T, Schwab N, Uçeyler N, Göbel K, Sommer C, Wiendl H. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2012;78:402–8.

    PubMed  CAS  Google Scholar 

  36. Misawa S, Kuwabara S, Mori M, Kawaguchi N, Yoshiyama Y, Hattori. Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology. 2001;56:666–9.

    PubMed  CAS  Google Scholar 

  37. Mei FJ, Ishizu T, Murai H, Osoegawa M, Minohara M, Zhang KN, et al. Th1shift in CIDP versus Th2 shift in vasculitic neuropathy in CSF. J Neurol Sci. 2005;228:75–85.

    PubMed  CAS  Google Scholar 

  38. Koski CL, Humphrey R, Shin ML. Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci USA. 1985;82:905–9.

    PubMed  CAS  Google Scholar 

  39. Van Doorn PA, Brand A, Vermeulen M. Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy. Neurology. 1987;37:1798–802.

    PubMed  Google Scholar 

  40. Fredman P, Bedeler CA, Nyland H, Aarli JA, Svennerholm L. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin. J Neurol. 1991;238:75–9.

    PubMed  CAS  Google Scholar 

  41. Ilyas AA, Mithen FA, Dalakas MC, Chen ZW, Cook SD. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 1992;107:111–21.

    PubMed  CAS  Google Scholar 

  42. Connolly AM, Pestronk A, Trotter JL, Feldman EL, Cornblath DR, Olney RK. High-titer selective serum anti-β-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology. 1993;43:557–62.

    PubMed  CAS  Google Scholar 

  43. Khalili-Shirazi A, Atkinson P, Gregson N, Hughes RAC. Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol. 1993;46:245–51.

    PubMed  CAS  Google Scholar 

  44. Manfredini E, Nobile-Orazio E, Allaria S, Scarlato G. Anti-alpha- and beta-tubulin IgM antibodies in dysimmune neuropathies. J eurol Sci. 1995;133:79–84.

    PubMed  CAS  Google Scholar 

  45. Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:286–92.

    PubMed  CAS  Google Scholar 

  46. Sanvito L, Makowska A, Mahdi-Rogers M, Hadden RD, Peakman M, Gregson N, et al. Humoral and cellular response to myelin ­protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2009;80:333–8.

    PubMed  CAS  Google Scholar 

  47. Harvey GK, Pollard JD, Schindhelm K, Antony J. Chronic experimental allergic neuritis: an electrophysiological and histological study in the rabbit. J Neurol Sci. 1987;81:215–25.

    PubMed  CAS  Google Scholar 

  48. Hattori N, Misu K, Koike H, Ichimura M, Nagamatsu M, Hirayama M, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001;184:57–63.

    PubMed  CAS  Google Scholar 

  49. Ruts L, Drenthen J, Jacobs BC, van Doorn PA, on behalf of the Dutch GBS Study Group. Distinguishing acute onset CIDP from fluctuating Guillain-Barré syndrome. A prospective study. Neurology. 2010;74:1680–6.

    PubMed  CAS  Google Scholar 

  50. Dionne A, Nicole MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve. 2010;42:202–7.

    Google Scholar 

  51. Boukhris S, Magy L, Khalil M, Sindou P, Vallat JM. Pain as the presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). J Neurol Sci. 2007;15(254):33–8.

    Google Scholar 

  52. Henderson RD, Sandroni P, Wijdicks EFM. Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol. 2005;252:1235–7.

    PubMed  Google Scholar 

  53. Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 1999;53:1648–54.

    PubMed  CAS  Google Scholar 

  54. Bissay V, Flamez A, Schmedding E, Ebinger G. Fatigue as the presenting symptom of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2008;38:1653–7.

    PubMed  Google Scholar 

  55. Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy. Neurology. 1998;50:1179–82.

    PubMed  CAS  Google Scholar 

  56. Stamboulis E, Katsaros N, Koutsis G, Iakovidou H, Giannakopoulou A, Simintzi I. Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2006;33:78–84.

    PubMed  Google Scholar 

  57. Midroni G, Dyck PJ. Chronic inflammatory demyelinating polyradiculoneuropathy: unusual clinical features and therapeutic responses. Neurology. 1996;46:1206–12.

    PubMed  CAS  Google Scholar 

  58. Ginsburg L, Platts AD, Thomas PK. Chronic inflammatory ­demyelinating polyneuropathy mimicking a lumbar spinal stenosis syndrome. J Neurol Neurosurg Psychiatry. 1995;59:189–91.

    Google Scholar 

  59. Goldstein JM, Parks BJ, Mayer PL, Kim JH, Sze G, Miller RG. Nerve root hypertrophy as the cause of lumbar stenosis in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1996;19:892–6.

    PubMed  CAS  Google Scholar 

  60. Schady W, Goulding PJ, Lecky BRF, King RHM, Smith CML. Massive nerve root enlargement in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1996;61:636–40.

    PubMed  CAS  Google Scholar 

  61. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain. 1995;118:359–68.

    PubMed  Google Scholar 

  62. Uncini A, Di Muzio A, De Angelis MV, Gioia S, Lugaresi A. Minimal and asymptomatic chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 1999;110:694–8.

    PubMed  CAS  Google Scholar 

  63. Bromberg MB. Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2011;43:780–94.

    PubMed  Google Scholar 

  64. Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, Graves M, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2009;277:1–8.

    PubMed  CAS  Google Scholar 

  65. Rajabally YA, Nicolas G, Piéret F, Bouche P, Van den Bergh PY. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry. 2009;80:1364–8.

    PubMed  CAS  Google Scholar 

  66. Ad hoc subcommittee of the American Academy of Neurology AIDS task force. Criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology. 1991;41:617–8.

    Google Scholar 

  67. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic infiammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst. 2010;15:1–9. Erratum in: J Peripher Nerv Syst. 2010;15:373.

    Google Scholar 

  68. Bromberg MB. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve. 1991;14:968–76.

    PubMed  CAS  Google Scholar 

  69. Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:592–601.

    Google Scholar 

  70. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision. J Peripher Nerv Syst. 2010;15:185–95.

    Google Scholar 

  71. Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology. 1982;32:592–6.

    PubMed  CAS  Google Scholar 

  72. Murphy SM, Laurá M, Blake J, Polke J, Bremner F, Reilly MM. Conduction block and tonic pupils in Charcot-Marie-Tooth disease caused by a myelin protein zero p.Ile112Thr mutation. Neuromuscul Disord. 2011;21:223–6.

    PubMed  Google Scholar 

  73. Yim SY, Lee IY, Moon HW, Rah UW, Kim SH, Shim C, et al. Hypertrophic neuropathy with complete conduction block – hereditary motor and sensory neuropathy type III. Yonsei Med J. 1995;36:466–72.

    PubMed  CAS  Google Scholar 

  74. Tamura N, Kuwabara S, Misawa S, Mori M, Nakata M, Hattor T. Superficial radial sensory nerve potentials in immune-mediated and diabetic neuropathies. Clin Neurophysiol. 2005;116:2330–3.

    PubMed  Google Scholar 

  75. Rajabally YA, Narasimhan M. The value of sensory electrophysiology in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2007;118:1999–2004.

    PubMed  Google Scholar 

  76. Bragg A, Benatar MG. Sensory nerve conduction slowing is a specific marker for CIDP. Muscle Nerve. 2008;38:1599–603.

    PubMed  Google Scholar 

  77. Yiannikas C, Vucic S. Utility of somatosensory evoked potentials in chronic acquired demyelinating neuropathy. Muscle Nerve. 2008;38:1447–54.

    PubMed  Google Scholar 

  78. Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJB. Chronic immune sensory polyradiculopathy. A possibly ­treatable sensory ataxia. Neurology. 2004;63:1662–9.

    PubMed  CAS  Google Scholar 

  79. Albers JW, Kelly JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve. 1989;12:435–51.

    PubMed  CAS  Google Scholar 

  80. Oh SJ. The single-fiber EMG in chronic demyelinating neuropathy. Muscle Nerve. 1989;12:371–7.

    PubMed  CAS  Google Scholar 

  81. Krendel DA, Parks HP, Anthony DC, St Clair MB, Graham DG. Sural nerve biopsy in chronic inflammatory demyelinating ­polyradiculoneuropathy. Muscle Nerve. 1989;12:257–64.

    PubMed  CAS  Google Scholar 

  82. Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka KV. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology. 2005;65:1924–9.

    PubMed  CAS  Google Scholar 

  83. De Silva RN, Willison HJ, Doyle D, Weir AI, Hadley DM, Thomas AM. Nerve root hypertrophy in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 1994;17:168–70.

    PubMed  Google Scholar 

  84. Mizuno K, Nagamatsu M, Hattori N, Yamamoto M, Goto H, Kuniyoshi K, et al. Chronic inflammatory demyelinating polyradiculoneuropathy with diffuse and massive peripheral nerve hypertrophy: distinctive clinical and magnetic resonance imaging features. Muscle Nerve. 1998;21:805–8.

    PubMed  CAS  Google Scholar 

  85. Duggins AJ, McLeod JG, Pollard JD, Davies L, Yang F, Thompson EO, et al. Spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy. Brain. 1999;122:1383–90.

    PubMed  Google Scholar 

  86. Matsuoka N, Kohriyama T, Ochi K, Nishitani M, Sueda Y, Mimori Y, et al. Detection of cervical nerve root hypertrophy by ­ultrasonography in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci. 2004;219:15–21.

    PubMed  Google Scholar 

  87. Imamura K, Tajiri Y, Kowa H, Nakashima K. Peripheral nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy detected by ultrasonography. Intern Med. 2009;48:581–2.

    PubMed  Google Scholar 

  88. Mendell JR, Kolkin S, Kissel JT, Weiss KL, Chakeres DW, Rammohan KW. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1987;37:1291–4.

    PubMed  CAS  Google Scholar 

  89. Thomas PK, Walker RWH, Rudge P, Morgan-Hughes JA, King RHM, Jacobs JM, et al. Chronic demyelinating peripheral ­neuropathy associated with multifocal central nervous system demyelination. Brain. 1987;110:53–76.

    PubMed  Google Scholar 

  90. Liguori R, Rizzi R, Vetrugno R, Salvi F, Lugaresi A, Cevoli S, et al. Steroid-responsive multifocal demyelinating neuropathy with central involvement. Muscle Nerve. 1999;22:262–5.

    PubMed  CAS  Google Scholar 

  91. Feasby TE, Hahn AF, Koopman WJ, Lee DH. Central lesions in chronic inflammatory polyneuropathy: an MRI study. Neurology. 1990;40:476–8.

    PubMed  CAS  Google Scholar 

  92. Hawke SHB, Hallinan JM, McLeod JG. Cranial magnetic resonance imaging in chronic demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1990;53:794–6.

    PubMed  CAS  Google Scholar 

  93. Ormerod IEC, Waddy HM, Kermode AG, Murray NMF, Thomas PK. Involvement of the central nervous system in chronic inflammatory demyelinating polyneuropathy: a clinical, electrophysiological and magnetic resonance imaging study. J Neurol Neurosurg Psychiatry. 1990;53:789–93.

    PubMed  CAS  Google Scholar 

  94. Oh SJ, Joy JL, Sunwoo I, Kuruoglu R. A case of chronic sensory demyelinating neuropathy responding to immunotherapies. Muscle Nerve. 1992;15:255–6.

    PubMed  CAS  Google Scholar 

  95. Oh SJ, Joy JL, Kuruoglu R. “Chronic sensory demyelinating neuropathy:” chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992;55:677–80.

    PubMed  CAS  Google Scholar 

  96. Simmons Z, Tivakaran S. Acquired demyelinating polyneuropathy presenting as a pure clinical sensory syndrome. Muscle Nerve. 1996;19:1174–6.

    PubMed  CAS  Google Scholar 

  97. Rubin M, Mackenzie CR. Clinically and electrodiagnostically pure sensory demyelinating polyneuropathy. Electromyogr Clin Neurophysiol. 1996;36:145–9.

    PubMed  CAS  Google Scholar 

  98. van Dijk GW, Notermans NC, Franssen H, Wokke JHJ. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. J Neurol. 1999;246:1134–9.

    PubMed  Google Scholar 

  99. Chin RL, Latov N, Sandr HW, Hays AP, Croul SE, Magda P, et al. Sensory CIDP presenting as cryptogenetic sensory polyneuropathy. J Peripher Nerv Syst. 2004;9:132–7.

    PubMed  Google Scholar 

  100. Larue S, Dashi F, Demeret S, Léger JM. Two patients with CIDP deteriorated after plasma exchange. J Peripher Nerv Syst. 2008;13:307.

    PubMed  Google Scholar 

  101. Sabatelli M, Madia F, Mignogna T, Lippi G, Quaranta L, Tonali P. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol. 2001;248:772–7.

    PubMed  CAS  Google Scholar 

  102. Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778–83.

    PubMed  CAS  Google Scholar 

  103. Kimura A, Sakurai T, Koumura A, Yamada M, Hayashi Y, Tanaka Y, et al. Motor—dominant chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010;257:621–9.

    PubMed  Google Scholar 

  104. Thomas PK, Claus D, Jaspert A, Workman JM, King RHM, Larner AJ, et al. Focal upper limb demyelinating neuropathy. Brain. 1996;119:765–74.

    PubMed  Google Scholar 

  105. Gorson KC, Ropper AH, Weinberg DH. Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 1999;22:758–65.

    PubMed  CAS  Google Scholar 

  106. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982;32:958–64.

    PubMed  CAS  Google Scholar 

  107. Gibbels E, Behse F, Kentenich M, Haupt WF. Chronic multifocal neuropathy with persistent conduction block (Lewis-Sumner syndrome). Clin Neuropathol. 1993;12:343–52.

    PubMed  CAS  Google Scholar 

  108. Oh SJ, Claussen GC, Kim DS. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy? J Peripher Nerv Syst. 1997;2:362–9.

    PubMed  CAS  Google Scholar 

  109. Saperstein DS, Amato AA, Wolfe GI, Katz JS, Nations SP, Jackson CE, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve. 1999;22:560–6.

    PubMed  CAS  Google Scholar 

  110. Van den Berg-Vos RM, Van den Berg LH, Franssen H, Vermeulen M, Witkamp TD, Jansen GH, et al. Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? Neurology. 2000;54:26–32.

    PubMed  Google Scholar 

  111. Verschueren A, Azulay JP, Attarian S, Boucraut J, Pellissier JF, Pouget J. Lewis-Sumner syndrome and multifocal motor neuropathy. Muscle Nerve. 2005;31:88–94.

    PubMed  Google Scholar 

  112. Viala K, Renié L, Maisonobe T, Béhin A, Neil J, Léger JM, et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain. 2004;127:2010–7.

    PubMed  CAS  Google Scholar 

  113. Rajabally Y, Chavada G. Lewis–Sumner syndrome of pure upper limb onset prognostic, diagnostic and therapeutic features. Muscle Nerve. 2009;39:206–20.

    PubMed  Google Scholar 

  114. Weiss MD, Oakley JC, Meekins GD. Hypoglossal neuropathy in Lewis-Sumner syndrome masquerading as motor neuron disease. Neurology. 2006;67:175–6.

    PubMed  CAS  Google Scholar 

  115. Oh SJ, LaGanke C, Powers R, Wolfe GI, Quinton RA, Burns DK. Multifocal motor sensory demyelinating neuropathy: inflammatory demyelinating polyradiculoneuropathy. Neurology. 2005;65:1639–42.

    PubMed  CAS  Google Scholar 

  116. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000;54:615–20.

    PubMed  CAS  Google Scholar 

  117. Larue S, Bombelli F, Viala K, Neil J, Maisonobe T, Bouche P, et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol. 2011;18:899–905.

    PubMed  CAS  Google Scholar 

  118. Carpo M, Meucci N, Allaria S, Marmiroli P, Monaco S, Toscano A, et al. Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci. 2000;176:144–50.

    PubMed  CAS  Google Scholar 

  119. Stewart JD, McKelvey R, Durcan L, Carpenter S, Karpati G. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci. 1996;142:59–64.

    PubMed  CAS  Google Scholar 

  120. Jann S, Bramerio MA, Facchetti D, Sterzi R. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J Neurol Neurosurg Psychiatry. 2009;80:70–3.

    PubMed  CAS  Google Scholar 

  121. Chiò A, Plano F, Calvo A, Leone M, Mutani R, Cocito D, et al. Comorbidity between CIDP and diabetes mellitus: only a matter of chance? Eur J Neurol. 2009;16:752–4.

    PubMed  Google Scholar 

  122. Pestronk A, Li F, Griffin J, Feldman EL, Cornblath D, Trotter J, et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology. 1991;41:357–62.

    PubMed  CAS  Google Scholar 

  123. Nobile-Orazio E, Manfredini E, Carpo M, Meucci N, Monaco S, Ferrari S, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 1994;36:416–24.

    PubMed  CAS  Google Scholar 

  124. Lopate G, Parks BJ, Goldstein MJ, Yee WC, Friesenhahn GM, Pestronk A. Polyneuropathy associated with high titers antisulfatide antibodies: characteristics of patients with and without serum monoclonal proteins. J Neurol Neurosurg Psychiatry. 1997;62:581–5.

    PubMed  CAS  Google Scholar 

  125. Ferrari S, Morbin M, Nobile-Orazio E, Musso A, Tomelleri G, Bertolasi L, et al. Anti-sulfatide neuropathy: antibody mediated complement attack to peripheral myelin. Acta Neuropathol. 1998;96:569–74.

    PubMed  CAS  Google Scholar 

  126. Bromberg MB, Feldman EL, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy. Neurology. 1992;42:1157–63.

    PubMed  CAS  Google Scholar 

  127. Nobile-Orazio E, Casellato C, Di Troia A. Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol. 2002;158:979–87.

    PubMed  CAS  Google Scholar 

  128. Di Troia A, Carpo M, Meucci N, Pellegrino C, Allaria S, Gemignani F, et al. Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J Neurol Sci. 1999;164:64–71.

    PubMed  Google Scholar 

  129. Allen D, Lunn MPT, Niermeijer J, Nobile-Orazio E. Treatment for IgG and IgA paraproteinemic neuropathy. Cochrane Database Syst Rev. 2007;(1):CD005376.

    Google Scholar 

  130. Gorson KC, Ropper AH, Weinberg DH, Weinstein R. Effect of intravenous immunoglobulin in patients with IgG monoclonal gammopathy. Arch Neurol. 2002;59:766–72.

    PubMed  Google Scholar 

  131. Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Eng J Med. 1991;325:1482–6.

    CAS  Google Scholar 

  132. Dalakas MC, Culper EJ. Neuropathies in HIV infection. Baillieres Clin Neurol. 1996;5:199–218.

    PubMed  CAS  Google Scholar 

  133. Antoine JC, Mosnier JF, Lapras J, Convers P, Absi L, Laurent B, et al. Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. J Neurol Neurosurg Psychiatry. 1996;60:188–90.

    PubMed  CAS  Google Scholar 

  134. Sugai F, Abe K, Fujimoto T, Nagano S, Fujimura H, Kayanoki Y, et al. Chronic inflammatory demyelinating polyneuropathy accompanied by hepatocellular carcinoma. Intern Med. 1997;36:53–5.

    PubMed  CAS  Google Scholar 

  135. Abe K, Sugai F. Chronic inflammatory demyelinating polyneuropathy accompanied by carcinoma. J Neurol Neurosurg Psychiatry. 1998;65:403–4.

    PubMed  CAS  Google Scholar 

  136. Greenspan BN, Felice KJ. Chronic inflammatory demyelinating polyneuropathy (CIDP) associated with seminoma. Eur Neurol. 1998;39:57–8.

    PubMed  CAS  Google Scholar 

  137. Bird SJ, Brown MJ, Shy ME, Scherer SS. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology. 1996;46:822–4.

    PubMed  CAS  Google Scholar 

  138. Weiss MD, Luciano CA, Semino-Mora C, Dalakas MC, Quarles RH. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology. 1998;51:1738–41.

    PubMed  CAS  Google Scholar 

  139. Lee JH, Sohn EH, Lee AY, Kim JM, Kim S. A case of chronic inflammatory demyelinating polyneuropathy associated with immune-mediated thrombocytopenia and cutaneous T-cell lymphoma. Clin Neurol Neurosurg. 2011;113:596–8.

    PubMed  Google Scholar 

  140. Isoda A, Sakurai A, Ogawa Y, Miyazawa Y, Saito A, Matsumoto M, et al. Chronic inflammatory demyelinating polyneuropathy accompanied by chronic myelomonocytic leukemia: possible pathogenesis of autoimmunity in myelodysplastic syndrome. Int J Hematol. 2009;90:239–42.

    PubMed  CAS  Google Scholar 

  141. Wada M, Kurita K, Tajima K, Kawanami T, Kato T. A case of inflammatory demyelinating polyradiculoneuropathy associated with T-cell lymphoma. Acta Neurol Scand. 2003;107:62–6.

    PubMed  CAS  Google Scholar 

  142. Collins MP, Dyck PJ, Gronseth GS, Guillevin L, Hadden RD, Heuss D, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15:176–84.

    PubMed  Google Scholar 

  143. Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17:289–94.

    PubMed  CAS  Google Scholar 

  144. Viala K, Maisonobe T, Stojkovic T, Koutlidis R, Ayrignac X, Musset L, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15:50–6.

    PubMed  CAS  Google Scholar 

  145. Donofrio PD, Berger A, Branaga 3rd TH, Bromberg MB, Howard JF, Latov N, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions. Report of the AANEM ad hoc committee. Muscle Nerve. 2009;40:890–900.

    PubMed  CAS  Google Scholar 

  146. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders. Neurology. 2012;78:1009–15.

    PubMed  CAS  Google Scholar 

  147. Hughes RAC, Bensa S, Willison HJ, van den Bergh P, Comi G, Illa I, et al. and the Inflammatory Neuropathy Cause and Treatment (INCAT) group. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195–201.

    PubMed  CAS  Google Scholar 

  148. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838–45.

    PubMed  CAS  Google Scholar 

  149. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebo-controlled trial. Lancet Neurol. 2008;7:136–44.

    PubMed  CAS  Google Scholar 

  150. Merkies IS, Bril V, Dalakas MC, Deng C, Donofrio P, Hanna K, et al. Health-related quality-of-life improvements in CIDP with immunoglobulin IV 10 %: the ICE study. Neurology. 2009;72:1337–44.

    PubMed  CAS  Google Scholar 

  151. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, et al. Pulsed high-dose dexamethasone ­versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind randomised controlled trial. Lancet Neurol. 2010;9:245–53.

    PubMed  Google Scholar 

  152. Eftimov F, Vermeulen M, van Doorn PA, Brusse E, Brusse E, van Schaik IN, et al. Long-term remission of CIDP after pulsed high-dose dexamethasone or short term prednisolone treatment. Neurology. 2012;78:1079–84.

    PubMed  CAS  Google Scholar 

  153. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11:493–502.

    PubMed  CAS  Google Scholar 

  154. McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas M, et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Eur J Neurol. 2003;10:687–94.

    PubMed  Google Scholar 

  155. Blackhouse G, Gaebel K, Xie F, Campbell K, Assasi N, Tarride JE, et al. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc. 2010;8:14.

    PubMed  Google Scholar 

  156. Mahdi-Rogers M, Swan AV, van Doorn PA, Hughes RAC. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2010;(11):CD003280.

    Google Scholar 

  157. Dyck PJ, O’Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology. 1985;35:1173–6.

    PubMed  CAS  Google Scholar 

  158. Hadden RDM, Sharrack B, Bensa S, Soudain SE, Hughes RA. Randomized trial of interferon β−1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1999;53:57–61.

    PubMed  CAS  Google Scholar 

  159. RMC Trial Group. Pilot randomised controlled trial of Methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial). Lancet Neurol. 2009;8:158–64.

    Google Scholar 

  160. Hughes RAC, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2010;74:651–7.

    PubMed  CAS  Google Scholar 

  161. Dyck PJ, O’Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136–44.

    PubMed  CAS  Google Scholar 

  162. Muley SA, Kelkar P, Parr GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol. 2008;65:1460–4.

    PubMed  Google Scholar 

  163. Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol. 2005;62:249–54.

    PubMed  Google Scholar 

  164. Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461–5.

    PubMed  CAS  Google Scholar 

  165. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain. 1996;119:1055–66.

    PubMed  Google Scholar 

  166. Donofrio PD, Tandan R, Albers JW. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1985;8:321–7.

    PubMed  CAS  Google Scholar 

  167. Choudhary PP, Hughes RA. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM. 1995;88:493–502.

    PubMed  CAS  Google Scholar 

  168. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993;56:36–9.

    PubMed  CAS  Google Scholar 

  169. Thompson N, Choudhary P, Hughes RAC, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 1996;243:280–5.

    PubMed  CAS  Google Scholar 

  170. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double blind, placebo-controlled, cross-over study. Brain. 1996;119:1067–77.

    PubMed  Google Scholar 

  171. Mendell JR, Barohn S, Freimer ML, Kissel JT, King W, Nagaraja HN, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56:445–9.

    PubMed  CAS  Google Scholar 

  172. Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67:802–7.

    PubMed  Google Scholar 

  173. Van Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990;40:209–12.

    PubMed  Google Scholar 

  174. Lee D-Y, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2008;37:406–9.

    PubMed  CAS  Google Scholar 

  175. Markvardsen LH, Harbo T, Sindrup S, Andersen H, Christiansen I, Olsen NK, et al. A randomized double-blind controlled trial of the effect of subcutaneous immunoglobulin on muscular performance in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2012;17:229.

    Google Scholar 

  176. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50:1778–83.

    PubMed  CAS  Google Scholar 

  177. Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, Benedetti L, et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol. 2011;18:1417–21.

    PubMed  CAS  Google Scholar 

  178. Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology. 1998;51:1735–8.

    PubMed  CAS  Google Scholar 

  179. Brannagan 3rd TH, Pradhan A, Heiman-Patterson T, Winkelman AC, Styler MJ, Topolsky DL, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology. 2002;58:1856–8.

    PubMed  CAS  Google Scholar 

  180. Gladstone DE, Prestrud AA, Brannagan 3rd TH. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2005;10:11–6.

    PubMed  CAS  Google Scholar 

  181. Hodgkinson SJ, Pollard JD, McLeod JG. Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 1990;53:327–30.

    PubMed  CAS  Google Scholar 

  182. Latov N, Sherman WH, Nemni R, Galassi G, Shyong JS, Penn AS, et al. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med. 1980;303:618–21.

    PubMed  CAS  Google Scholar 

  183. Braun PE, Frail DE, Latov N. Myelin associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem. 1982;39:1261–5.

    PubMed  CAS  Google Scholar 

  184. Trapp BD. Myelin-associated glycoprotein. Location and ­potential functions. Ann NY Acad Sci. 1990;605:29–43.

    PubMed  CAS  Google Scholar 

  185. Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol. 1988;3:301–32.

    PubMed  CAS  Google Scholar 

  186. Ariga T, Kohiriyama T, Freddo L, Latov N, Saito M, Kon K, et al. Characterization of sulfated glucuronic acid containing ­glycolipids reacting with IgM M-proteins in patients with neuropathy. J Biol Chem. 1987;262:848–53.

    PubMed  CAS  Google Scholar 

  187. Bollensen E, Steck AJ, Schachner M. Reactivity with the peripheral myelin glycoprotein P0 in serum from patients with monoclonal IgM gammopathy and polyneuropathy. Neurology. 1988;38:1266–70.

    PubMed  CAS  Google Scholar 

  188. Burger D, Simon M, Perruisseau G, Stck AJ. The epitope(s) recognized by HNK-1 antibody and IgM paraprotein in neuropathy is present on several N-linked oligosaccharide structures on human P0 and myelin-associated glycoprotein. J Neurochem. 1990;54:1569–75.

    PubMed  CAS  Google Scholar 

  189. Snipes GJ, Suter U, Shooter EM. Human peripheral myelin protein-22 carries the L2/HNK1 carbohydrate adhesion epitope. J Neurochem. 1993;61:1961–4.

    PubMed  CAS  Google Scholar 

  190. Nobile-Orazio E. Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ, editors. Immunological and infectious diseases of the peripheral nerve. Cambridge: Cambridge University Press; 1998. p. 169–89.

    Google Scholar 

  191. Baldini L, Nobile-Orazio E, Guffanti A, Barbieri S, Carpo M, Cro L, et al. Peripheral neuropathy in IgM monoclonal gammopathy and Waldenstrom Macroglobulinemia: a frequent complication in males with low MAG-reactive serum monoclonal component. Am J Hematol. 1994;45:25–31.

    PubMed  CAS  Google Scholar 

  192. Bain PG, Britton TC, Jenkins IH, Thompson PD, Rothwell JC, Thomas PK, et al. Tremor associated with IgM paraproteinemic neuropathy. Brain. 1996;119:789–99.

    PubMed  Google Scholar 

  193. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relation with immune therapies. Brain. 2000;123:710–7.

    PubMed  Google Scholar 

  194. Niermeijer JMF, Fischer K, Eurelings M, Franssen H, Wokke JH, Notermans NC. Prognosis of polyneuropathy due to IgM monoclonal gammopathy. Neurology. 2010;74:406–12.

    PubMed  CAS  Google Scholar 

  195. Kuijf ML, Eurelings M, Tio-Gillen AP, van Doorn PA, van den Berg LH, Hooijkaas H, et al. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology. 2009;73:688–95.

    PubMed  CAS  Google Scholar 

  196. Chassande B, Léger J-M, Ben Younes-Chenouffi A, Bengoufa D, Maisonobe T, Bouche P, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve. 1998;21:55–62.

    PubMed  CAS  Google Scholar 

  197. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain. 1994;117:941–7.

    PubMed  Google Scholar 

  198. Franssen H, Notermans NC. Length dependence in polyneuropathy associated with IgM gammopathy. Ann Neurol. 2006;59:365–71.

    PubMed  Google Scholar 

  199. Capasso M, Torrieri F, Di Muzio A, De Angelis MV, Lugaresi A, Uncini A. Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy? Clin Neurophysiol. 2002;113:346–53.

    PubMed  CAS  Google Scholar 

  200. Vital A, Vital C, Julien J, Baquey A, Steck AJ. Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients. Acta Neuropathol. 1989;79:160–7.

    PubMed  CAS  Google Scholar 

  201. Takatsu M, Hays AP, Latov N, Abrams GM, Nemni R, Sherman WH, et al. Immunofluorescence study of patients with neuropathy and IgM M-proteins. Ann Neurol. 1985;18:173–81.

    PubMed  CAS  Google Scholar 

  202. Monaco S, Bonetti B, Ferrari S, Moretto G, Nardelli E, Tedesco F, et al. Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med. 1990;322:649–52.

    PubMed  CAS  Google Scholar 

  203. Lombardi R, Erne B, Lauria G, Pareyson D, Borgna M, Morbin M, et al. IgM deposits on skin nerves in anti-myelin associated glycoprotein neuropathy. Ann Neurol. 2005;57:180–7.

    PubMed  CAS  Google Scholar 

  204. Meucci N, Baldini L, Cappelari A, Di Troia A, Allaria S, Scarlato G, et al. Anti-MAG antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy. Ann Neurol. 1999;46:119–22.

    PubMed  CAS  Google Scholar 

  205. Gabriel J-M, Erne B, Miescher GC, Miller SL, Vital A, Vital C, et al. Selective loss of myelin-associated glycoprotein from myelin correlates with anti-MAG antibody titre in demyelinating paraproteinemic polyneuropathy. Brain. 1996;119:775–87.

    PubMed  Google Scholar 

  206. Hays AP, Latov N, Takatsu M, Sherman WH. Experimental demyelination of nerve induced by serum of patients with neuropathy and anti-MAG IgM M-proteins. Neurology. 1987;37:242–6.

    PubMed  CAS  Google Scholar 

  207. Tatum AH. Experimental paraprotein neuropathy; demyelination by passive transfer of human anti-myelin-associated glycoprotein. Ann Neurol. 1993;33:502–6.

    PubMed  CAS  Google Scholar 

  208. Willison HJ, Trapp BD, Bacher JD, Dalakas MC, Griffin JW, Quarles RH. Demyelination induced by intraneural injection of human anti-myelin-associated glycoprotein antibodies. Muscle Nerve. 1988;11:1169–76.

    PubMed  CAS  Google Scholar 

  209. Monaco S, Ferrari S, Bonetti B, Moretto G, Kirshfink M, Nardelli E, et al. Experimental induction of myelin changes by anti-MAG antibodies and terminal complement complex. J Neuropathol Exp Neurol. 1995;54:96–104.

    PubMed  CAS  Google Scholar 

  210. Ilyas AA, Gu Y, Dalakas MC, Quarles RH, Bhatt S. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol. 2008;193:87–93.

    PubMed  CAS  Google Scholar 

  211. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2012;(5):CD002827.

    Google Scholar 

  212. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485–9.

    PubMed  CAS  Google Scholar 

  213. Renaud S, Fuhr P, Gregor M, Schweikert K, Lorenz D, Daniels C, et al. High-dose rituximab and anti-MAG associated polyneuropathy. Neurology. 2006;66:742–4.

    PubMed  CAS  Google Scholar 

  214. Benedetti L, Briani C, Grandis M, Vigo T, Gobbi M, Ghiglione E, et al. Predictors of response to Rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst. 2007;12:102–7.

    PubMed  CAS  Google Scholar 

  215. Niermeijer JM, Eurelings M, Lokhorst HL, van der Pol WL, Franssen H, Wokke JH, et al. Rituximab for polyneuropathy with IgM monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 2009;80:1036–9.

    PubMed  CAS  Google Scholar 

  216. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo controlled trial of Rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286–93.

    PubMed  CAS  Google Scholar 

  217. Léger J-M, Viala K, Bombelli F, Nicolas G, Créange A, Vallat J-M, et al. A randomized controlled trial of Rituximab in demyelinating neuropathy associated with anti-MAG IgM gammopathy (RIMAG STUDY). J Peripher Nerv Syst. 2010;15:269 (abstract).

    Google Scholar 

  218. Benedetti L, Briani C, Franciotta D, Carpo M, Padua L, Zara G, et al. Long-term effect of Rituximab in anti-MAG polyneuropathy. Neurology. 2008;71:1742–4.

    PubMed  CAS  Google Scholar 

  219. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports project. Blood. 2009;113:4834–40.

    PubMed  CAS  Google Scholar 

  220. Gruson B, Ghomari K, Beaumont M, Garidi R, Just A, Merle P, et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst. 2011;16:180–5.

    PubMed  CAS  Google Scholar 

  221. Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73–8.

    PubMed  CAS  Google Scholar 

  222. Chad DA, Hammer K, Sargent J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology. 1986;36:1260–3.

    PubMed  CAS  Google Scholar 

  223. Roth G, Rohr J, Magistris MR, Ochsner F. Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Eur Neurol. 1986;25:416–23.

    PubMed  CAS  Google Scholar 

  224. Parry GJ, Clark S. Multifocal acquired demyelinating neuropathy masquerading as a motor neuron disease. Muscle Nerve. 1988;11:103–7.

    PubMed  CAS  Google Scholar 

  225. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2005;(2):CD004429.

    Google Scholar 

  226. Umapathi T, Hughes R, Nobile-Orazio E, Leger J. Immuno­suppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev. 2009;(1):CD003217.

    Google Scholar 

  227. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve. 2005;31:663–80.

    PubMed  Google Scholar 

  228. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. Lancet Neurol. 2005;4:309–19.

    PubMed  Google Scholar 

  229. Cats EA, van der Pol WL, Piepers S, Franssen H, Jacobs BC, van den Berg-Vos RM, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75:818–25.

    PubMed  CAS  Google Scholar 

  230. Manganelli F, Pisciotta C, Iodice R, Calandro S, Santoro L. Nine-year case history of monofocal motor neuropathy. Muscle Nerve. 2008;38:927–9.

    PubMed  Google Scholar 

  231. Bouche P, Moulonguet A, Younes-Chennoufi AB, Adams D, Bauman N, Meininger V, et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry. 1995;59:38–44.

    PubMed  CAS  Google Scholar 

  232. Taylor BV, Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve. 2000;23:900–8.

    PubMed  CAS  Google Scholar 

  233. Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile-Orazio E. How long is IVIg effective in multifocal motor neuropathy? Neurology. 2004;62:666–8.

    PubMed  CAS  Google Scholar 

  234. Olney RK, Lewis RA, Putnam TD, Campellone JV. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve. 2003;27:117–21.

    PubMed  Google Scholar 

  235. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. First revision. J Peripher Nerv Syst. 2010;15:295–301.

    Google Scholar 

  236. Kimura J. Principles and pitfalls of nerve conduction studies. Ann Neurol. 1984;16:415–29.

    PubMed  CAS  Google Scholar 

  237. Cappellari A, Nobile-Orazio E, Meucci N, Scarlato G, Barbieri S. Criteria for the early detection of conduction block in multifocal motor neuropathy (MMN): a study based on control populations and follow-up of MMN patients. J Neurol. 1997;244:625–30.

    PubMed  CAS  Google Scholar 

  238. Cornblath DR, Sumner AJ, Daube J, Gilliat RW, Brown WF, Parry GJ, et al. Conduction block in clinical practice. Muscle Nerve. 1991;14:869–71.

    PubMed  CAS  Google Scholar 

  239. Olney RK. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve. 1999;22 Suppl 8Suppl 8:S225–9.

    Google Scholar 

  240. Arunachalam R, Osei-Lah A, Mills KR. Transcutaneous cervical root stimulation in the diagnosis of multifocal motor neuropathy with conduction block. J Neurol Neurosurg Psychiatry. 2003;74:1329–31.

    PubMed  CAS  Google Scholar 

  241. Akaza M, Kanouchi T, Inaba A, Numasawa Y, Irioka T, Mizusawa H, et al. Motor nerve conduction study in cauda equina with high-voltage electrical stimulation in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve. 2011;43:274–82.

    PubMed  Google Scholar 

  242. Nodera H, Bostock H, Yzumi Y, Nakamura K, Urushihara R, Sakamoto T, et al. Activity-dependent conduction block in multifocal motor neuropathy. Magnetic fatigue test. Neurology. 2006;67:280–7.

    PubMed  CAS  Google Scholar 

  243. Deroide N, Uzenot D, Verscheuren A, Azulay JP, Pouget J, Attarian S. Triple-stimulation technique in multifocal motor neuropathy with conduction block. Muscle Nerve. 2007;35:632–6.

    PubMed  Google Scholar 

  244. Cappellari A, Nobile-Orazio E, Meucci N, Scarlato G, Barbieri S. Multifocal motor neuropathy: a source of error in the serial evaluation of conduction block. Muscle Nerve. 1996;19:666–9.

    PubMed  CAS  Google Scholar 

  245. Valls-Solé J, Cruz Martinez A, Graus F, Saiz A, Arpa J, Grau JM. Abnormal sensory conduction in multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1995;45:2024–8.

    PubMed  Google Scholar 

  246. Delmont E, Benaïm C, Launay M, Sacconi S, Soriani MH, Desnuelle C. Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition? J Neurol. 2009;256:1876–80.

    PubMed  Google Scholar 

  247. Lambrecq V, Krim E, Rouanet-Larrivière M, Lagueny A. Sensory loss in multifocal motor neuropathy: a clinical and electrophysiological study. Muscle Nerve. 2009;39:131–6.

    PubMed  Google Scholar 

  248. Lievens I, Fournier E, Viala K, Maisonobe T, Bouche P, Léger JM. Multifocal motor neuropathy: a retrospective study of sensory nerve conduction velocities in long-term follow-up of 21 patients (Article in French). Rev Neurol. 2009;165:243–8.

    PubMed  CAS  Google Scholar 

  249. Van den Berg-Vos RM, Franssen H, Wokke JHJ, Van Es HW, Van den Berg LH. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin. Neurology. 2000;48:919–26.

    Google Scholar 

  250. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol. 2001;115:4–18.

    PubMed  CAS  Google Scholar 

  251. Gooch CL, Amato AA. Are anti-ganglioside antibodies of clinical value in multifocal motor neuropathy? Neurology. 2010;75:1950–1.

    PubMed  Google Scholar 

  252. Bech E, Andersen H, Orntoft TF, Jakobsen J. Association of IgM type anti-GM1 antibodies and muscle strength in chronic acquired demyelinating polyneuropathy. Ann Neurol. 1998;43:72–8.

    PubMed  CAS  Google Scholar 

  253. Nobile-Orazio E, Gallia F, Terenghi F, Allaria S, Giannotta C, Carpo M. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci. 2008;266:156–63.

    PubMed  CAS  Google Scholar 

  254. Taylor BV, Gross LA, Windebank AJ. The sensitivity and specificity of anti-GM1 antibody testing. Neurology. 1996;47:951–5.

    PubMed  CAS  Google Scholar 

  255. van Schaik IN, Bossuyt PMM, Brand A, Vermeulen M. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta analysis. Neurology. 1995;45:1570–7.

    PubMed  Google Scholar 

  256. Kuijf ML, van Doorn PA, Tio-Gillen AP, Geleijns K, Ang CW, Hooijkaas H, et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci. 2005;239:37–44.

    PubMed  CAS  Google Scholar 

  257. Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology. 1997;49:1289–92.

    PubMed  CAS  Google Scholar 

  258. Pestronk A, Choksi R, Blume G, Lopate G. Multifocal motor neuropathy: serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to GM1 alone. Neurology. 1997;48:1104–6.

    PubMed  CAS  Google Scholar 

  259. Nobile-Orazio E, Gianotta C. Testing for IgM antibodies to GM1-galactocerebroside complex increases the sensitivity of anti-GM1 IgM in multifocal motor neuropathy. Neurology. 2011;76 Suppl 4Suppl 4:A573.

    Google Scholar 

  260. Pestronk A, Chuquilin M, Choski R. Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside. J Neurol Neurosurg Psychiatry. 2010;81:726–30.

    PubMed  Google Scholar 

  261. Giannotta C, Musset L, Léger JM, Nobile-Orazio E. Antibody testing in multifocal motor neuropathy. J Peripher Nerv Syst. 2012;17:241–2.

    Google Scholar 

  262. Van Es HW, Van den Berg LH, Franssen H, Witkamp TD, Ramos LM, Notermans NC, et al. Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology. 1997;48:1218–24.

    PubMed  Google Scholar 

  263. Beekman R, van den Berg LH, Franssen H, Visser LH, van Asseldonk JT, Wokke JH. Ultrasonography shows extensive nerve enlargements in multifocal motor neuropathy. Neurology. 2005;65:305–7.

    PubMed  CAS  Google Scholar 

  264. Corse AM, Chaudry W, Crawford TO, Cornblath DR, Kuncl RW, Griffin JW. Sural nerve pathology in multifocal motor neuropathy. Ann Neurol. 1996;39:319–25.

    PubMed  CAS  Google Scholar 

  265. Auer RN, Bell RB, Lee MA. Neuropathy with onion bulb formations and pure motor manifestations. Can J Neurol Sci. 1989;16:194–7.

    PubMed  CAS  Google Scholar 

  266. Kaji R, Nobuyuki O, Tsuji T, Mezaki T, Nishio T, Akiguchi I, et al. Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol. 1993;33:152–8.

    PubMed  CAS  Google Scholar 

  267. Taylor BV, Dyck PJB, Engelstand J, Gruener G, Grant I, Dyck PJ. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol. 2004;63:129–37.

    PubMed  Google Scholar 

  268. Corbo M, Abouzahr MK, Latov N, Iannaccone S, Quattrini A, Nemni R, et al. Motor nerve biopsy studies in motor neuropathy and motor neuron disease. Muscle Nerve. 1997;120:15–21.

    Google Scholar 

  269. Riva N, Iannaccone S, Corbo M, Casellato C, Sferrazza B, Lazzerini A, et al. Motor nerve biopsy: clinical usefulness and histopathological criteria. Ann Neurol. 2011;69:197–201.

    PubMed  Google Scholar 

  270. Santoro M, Uncini A, Corbo M, Staugaitis SM, Thomas FP, Hays AP, et al. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol. 1992;31:385–90.

    PubMed  CAS  Google Scholar 

  271. Uncini A, Santoro M, Corbo M, Lugaresi A, Latov N. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve. 1993;16:610–5.

    PubMed  CAS  Google Scholar 

  272. Arasaki K, Kusunoki S, Kudo N, Kanazawa I. Acute conduction block in vitro following exposure to anti-ganglioside sera. Muscle Nerve. 1993;16:587–93.

    PubMed  CAS  Google Scholar 

  273. Paparounas K, O’Hanlon GM, Rowan EG, Willison HJ. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain. 1999;122:807–16.

    PubMed  Google Scholar 

  274. Roberts M, Willison HJ, Vincent A, Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol. 1995;38:111–8.

    PubMed  CAS  Google Scholar 

  275. Azulay J-P, Blin O, Pouget J, Boucraut J, Billé-Turc F, Carles G, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo controlled study. Neurology. 1994;44:429–32.

    PubMed  CAS  Google Scholar 

  276. Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;59:248–52.

    PubMed  Google Scholar 

  277. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg. Randomized, double-blind, placebo-controlled, study. Neurology. 2000;55:1257–62.

    Google Scholar 

  278. Léger J-M, Chassande B, Musset L, Meininger V, Bouche P, Bauman N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind placebo-controlled study. Brain. 2001;124:145–53.

    PubMed  Google Scholar 

  279. Hahn AF, Beydoun SR, Lawson V, Oh M, Empson VG, Gelmont D, et al. for the IVIg in MMN Study Team. A phase III randomized, placebo-controlled study of the efficacy and safety of 10 % liquid intravenous immunoglobulin (IVIg) for the treatment of multifocal motor neuropathy. J Peripher Nerv Syst. 2012;17:243–4.

    Google Scholar 

  280. Azulay JP, Rihet P, Pouget J, Cador F, Blin O, Boucraut J, et al. Long-term follow-up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry. 1997;62:391–4.

    PubMed  CAS  Google Scholar 

  281. Van den Berg-Vos RM, Franssen H, Wokke JHJ, Van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain. 2002;125:1875–86.

    PubMed  Google Scholar 

  282. Vucic S, Black KR, Chong PS, Cros D. Multifocal motor neuropathy. Decrease in conduction blocks and reinnervation with long-term IVIg. Neurology. 2004;63:1264–9.

    PubMed  Google Scholar 

  283. Léger JM, Viala K, Cancalon F, Maisonobe T, Gruwez B, Waegemans T, et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry. 2008;79:93–6.

    PubMed  Google Scholar 

  284. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized single–blinded cross-over trial. Eur J Neurol. 2009;16:631–8.

    PubMed  CAS  Google Scholar 

  285. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst. 2009;14:93–100.

    PubMed  CAS  Google Scholar 

  286. Lehmann HC, Hoffmann FR, Fusshoeller A, Meyer zu Hörste G, Hetzel R, Hartung HP, et al. The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci. 2008;271:34–9.

    PubMed  CAS  Google Scholar 

  287. Carpo M, Cappellari A, Mora G, Pedotti R, Barbieri S, Scarlato G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology. 1998;50:1480–2.

    PubMed  CAS  Google Scholar 

  288. Feldman EL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol. 1991;30:397–401.

    PubMed  CAS  Google Scholar 

  289. Van den Berg-Vos RM, Van den Berg LH, Franssen H, Van Doorn PA, Merkies ISJ, Wokke JHJ. Treatment of multifocal motor ­neuropathy with interferon-β1A. Neurology. 2000;54:1518–21.

    PubMed  Google Scholar 

  290. Radziwill AJ, Botez S, Novy J, Kuntzer T. Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial. J Peripher Nerv Syst. 2009;14:201–2.

    PubMed  Google Scholar 

  291. Piepers S, Van den Berg-Vos R, Van der Pol W-L, Franssen H, Wokke J, Van den Berg L. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain. 2007;130:2004–10.

    PubMed  Google Scholar 

  292. Nobile-Orazio E, Terenghi F, Cocito D, Gallia F, Casellato C. Oral Methotrexate as adjunctive therapy in patients with multifocal motor neuropathy on chronic IVIg therapy. J Peripher Nerv Syst. 2009;14:203–5.

    PubMed  CAS  Google Scholar 

  293. Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011;16:84–91.

    PubMed  Google Scholar 

  294. Stielgbauer K, Topakian R, Hinterberger G, Aichner FT. Beneficial effect of rituximab therapy in multifocal motor neuropathy. Neuromuscul Disord. 2009;19:473–5.

    Google Scholar 

  295. Chaudhry V, Cornblath DR. An open label trial of Rituximab (Rituxan®) in multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15:196–201.

    PubMed  CAS  Google Scholar 

  296. Umapathi T, Hughes R, Nobile-Orazio E, Leger J. Immuno­suppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev. 2012;(4):CD003217.

    Google Scholar 

  297. Katz JS, Wolfe GI, Bryan WW, Jackson CE, Amato AA, Barohn RJ. Electrophysiologic findings in multifocal motor neuropathy. Neurology. 1997;48:700–7.

    PubMed  CAS  Google Scholar 

  298. Pakiam ASI, Parry GJ. Multifocal motor neuropathy without overt conduction block. Muscle Nerve. 1998;21:243–5.

    PubMed  CAS  Google Scholar 

  299. Nobile-Orazio E, Meucci N, Carpo M, Terenghi F, Bersano A, Cappellari A, et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry. 2002;72:761–6.

    PubMed  CAS  Google Scholar 

  300. Delmont E, Azulay JP, Giorgi R, Attarian S, Verschueren A, Uzenot D, et al. Multifocal motor neuropathy with and without conduction block: a single entity? Neurology. 2006;67:592–6.

    PubMed  CAS  Google Scholar 

  301. Katz JS, Barohn RJ, Kojan S, Wolfe GI, Nations SP, Saperstein DS, et al. Axonal multifocal motor neuropathy without conduction block or other features of demyelination. Neurology. 2002;58:615–20.

    PubMed  CAS  Google Scholar 

  302. Riva N, Gallia F, Iannaccone S, Terenghi F, Lazzerini A, Cerri F, et al. Chronic motor axonal neuropathy. J Peripher Nerv Syst. 2011;16:341–6.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biotechnology and Translational Medicine (BIOMETRA), Milan University, 2nd Neurology, IRCCS Humanitas Clinical Institute, Via Manzoni 56, 20089, Milan, Rozzano, Italy

    Eduardo Nobile-Orazio MD, PhD, FAAN, Francesca Gallia MD & Elda Judica MD

Authors
  1. Eduardo Nobile-Orazio MD, PhD, FAAN
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Gallia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elda Judica MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduardo Nobile-Orazio MD, PhD, FAAN .

Editor information

Editors and Affiliations

  1. School of Medicine Department of Neurology, University Hospitals Case Medical Center Case Western Reserve University, Cleveland, Ohio, USA

    Bashar Katirji

  2. Department of Neurology, George Washington University, Washington, District of Columbia, USA

    Henry J. Kaminski

  3. University School of Medicine Department of Neurology, Louis Stokes Cleveland VA Medical Center Case Western Reserve, Cleveland, Ohio, USA

    Robert L. Ruff

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Nobile-Orazio, E., Gallia, F., Judica, E. (2014). Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Related Disorders. In: Katirji, B., Kaminski, H., Ruff, R. (eds) Neuromuscular Disorders in Clinical Practice. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6567-6_29

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6567-6_29

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6566-9

  • Online ISBN: 978-1-4614-6567-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation